Shukra Pharmaceuticals valuation

Share price at each year-end
Tap a line for its trendCurrentlast closeFY24Mar 2024FY23Mar 2023
Price multiples — at each FY-end close
3.13×——
1.01×——
0.78×——
Enterprise multiples
0.68×——
2.61×——
2.92×——
Yield
0.1%——
32.0%——
−12.0%——
Reference — adjusted share basis
₹71.92——
₹23.00₹23.00₹5.47
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SHUKRAPHAR₹71.92

Shukra Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSUNLOCMcap ₹58 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
Current
last close
Price Multiples — at each FY-end close
P/E——3.13
P/B——1.01
P/Sales——0.78
Enterprise Multiples
EV/Sales——0.68
EV/EBITDA——2.61
EV/EBIT——2.92
Yield
Dividend Yield %——0.12
Earnings Yield %——31.98
FCF Yield %——-12.00
Reference — adjusted share basis
Price (FY-end close, adj.)——71.92
EPS (adj.)5.4723.0023.00
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.